Application and Effect Evaluation of Integrated Nursing and Medical Management in Pediatric Lobar Pneumonia

Integrated nursing and medical management significantly improves clinical symptoms and pulmonary function in children with lobar pneumonia, shortens hospitalization duration, reduces complication rates, and enhances caregiver satisfaction. These findings support its broad clinical applicability and value.

Study Overview

• Status: Completed
• Conditions: Satisfaction; Pediatrics; Inflammatory Markers; Lobar Pneumonia
• Intervention / Treatment: Other: control group; Other: observation group

Detailed Description

This study aims to evaluate the clinical efficacy of integrated nursing and medical management in the treatment of pediatric lobar pneumonia. Specifically, it assesses its impact on symptom relief, pulmonary function recovery, inflammatory response control, duration of hospitalization, and caregiver satisfaction. Fifty pediatric patients diagnosed with lobar pneumonia and admitted to our hospital between January and December 2023 were selected and randomly assigned to either the observation group or the control group (n = 25 each) using a random number table. The control group received routine nursing care, while the observation group was additionally managed with an integrated nursing and medical approach. The two groups were compared in terms of duration of fever, cough, pulmonary rales, antibiotic treatment, length of hospital stay, pulmonary function parameters (FEV₁, FVC, FEV₁/FVC), inflammatory markers (CRP, WBC, PCT, LDH), overall treatment efficacy, caregiver satisfaction, and incidence of adverse events.

• Study Type: Observational
• Enrollment (Actual): 50

Contacts and Locations

Study Locations

• China
  • Shijiazhuang, China, 050000
    • Hebei Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Fifty pediatric patients diagnosed with lobar pneumonia and admitted to our hospital between January and December 2023 were selected and randomly assigned to either the observation group or the control group (n = 25 each) using a random number table.

Description

Inclusion Criteria:

• (1) Met the diagnostic criteria for lobar pneumonia, presenting with symptoms such as fever, cough, and pulmonary rales, and confirmed by laboratory tests and chest X-ray;
• (2) Aged between 1 and 12 years;
• (3) Informed consent was obtained from the child's legal guardians.

Exclusion Criteria:

• (1)Presence of other concurrent respiratory diseases;
• (2) Congenital or acquired airway malformations, or airway foreign bodies;
• (3) Impaired hepatic or renal function;
• (4) Presence of other systemic diseases;
• (5) Cognitive impairment.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
control group; The control group received routine nursing care	Other: control group; The control group received routine nursing care
observation group; the observation group was additionally managed with an integrated nursing and medical approach.	Other: observation group; the observation group was additionally managed with an integrated nursing and medical approach.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Clinical Resolution of Symptoms	Duration (in days) from hospital admission until resolution of three key symptoms: fever (axillary temperature <37.3°C for 24h), cough (absence of cough for 48h), and pulmonary rales (absence on auscultation). Assessed daily by blinded clinicians.	From admission until discharge (up to 14 days).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Pulmonary Function (FEV₁, FVC, FEV₁/FVC)	Absolute change in spirometry-measured FEV₁ (L), FVC (L), and FEV₁/FVC ratio (%) from admission to discharge. Assessed using standardized spirometry protocols.	Baseline (T0) and discharge (T1; up to 14 days).
Reduction in Inflammatory Markers (CRP, PCT, WBC, LDH)	Percent reduction in serum CRP (mg/L), PCT (ng/mL), WBC (×10⁹/L), and LDH (U/L) levels from admission to discharge.	Baseline (T0) and discharge (T1; up to 14 days).
Length of Hospital Stay	Total days from admission to discharge, documented from electronic health records.	Up to 14 days.
Parental Satisfaction Rate	Proportion of caregivers reporting "very satisfied" or "satisfied" on a 4-point Likert scale (very satisfied/satisfied/neutral/dissatisfied) at discharge.	At discharge (T1; up to 14 days).

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Complications	Proportion of patients experiencing adverse events (e.g., hemoptysis, pneumothorax, bronchospasm) during hospitalization, verified by imaging/lab reports.	From admission to discharge (up to 14 days).
Antibiotic Usage Duration	Total days of intravenous/oral antibiotic therapy, recorded from medication logs.	From admission to discontinuation (up to 14 days).
Adherence to Rehabilitation Protocols	Compliance with respiratory exercises (e.g., % of scheduled postural drainage sessions completed), tracked via nursing logs.	Daily during hospitalization (up to 14 days).

Collaborators and Investigators

• Sponsor: Children's Hospital of Hebei Province

Study record dates

Study Major Dates

• Study Start (Actual): January 13, 2023
• Primary Completion (Actual): March 20, 2024
• Study Completion (Actual): October 18, 2024

Study Registration Dates

• First Submitted: April 16, 2025
• First Submitted That Met QC Criteria: April 22, 2025
• First Posted (Actual): April 27, 2025

Study Record Updates

• Last Update Posted (Actual): April 27, 2025
• Last Update Submitted That Met QC Criteria: April 22, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: No. 202222-17

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No